Ramsey Falconer, MD
Neurology · Alexandria, VANPI 1275859688
Payments from drug & device makers
Across 2,416 payments — averaging $975.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$529K
- Amneal Pharmaceuticals LLC$518K
- Kyowa Kirin, Inc.$268K
- Abbott$182K
- Acorda Therapeutics, Inc$148K
- UCB SA$139K
- plus $573K from 44 others
Across 8 payments — averaging $7370.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$23K
- Neurocrine Biosciences, Inc.$22K
- Acadia Pharmaceuticals Inc$14K
What the payments were for
- Consulting fees$367,25718%
- Speaking & faculty fees$1,447,66373%
- Travel & lodging$129,0016%
- Food & beverage$35,0782%
- Education$11,1411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$413,524
- RYTARY$285,214
- NOURIANZ$264,902
- INBRIJA$176,368
- ONGENTYS$131,579
- CREXONT$83,522
- GOCOVRI$82,376
- NUPLAZID$70,291
- Neuromodulation Dspsbls and Accs$53,876
- Infinity DBS Pulse Generators$49,527
- INFINITY$45,183
- Duopa$40,577
- PERCEPT PC BRAINSENSE$37,185
- XEOMIN$29,089
- NUEDEXTA$23,946
- VYALEV$12,142
- KYNMOBI$11,506
- Neupro$8,112
- LONHALA MAGNAIR$5,250
- NORTHERA$4,919
How this compares
$2,355,983 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 812 | $1,538,943 |
| NuplazidPimavanserin Tartrate | 227 | $1,400,907 |
| GocovriAmantadine Hcl | 141 | $617,342 |
| NourianzIstradefylline | 178 | $531,933 |
| IngrezzaValbenazine Tosylate | 29 | $284,941 |
| TasignaNilotinib Hcl | 16 | $161,584 |
| NeuproRotigotine | 57 | $122,290 |
| NuedextaDextromethorphan Hbr/Quinidine | 46 | $118,276 |
| OngentysOpicapone | 60 | $103,837 |
| CrexontCarbidopa/Levodopa | 78 | $102,571 |
| Droxidopa | 11 | $99,918 |
| XadagoSafinamide Mesylate | 41 | $88,339 |
| InbrijaLevodopa | 18 | $81,846 |
| Rivastigmine | 186 | $64,630 |
| Rasagiline Mesylate | 262 | $50,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide | $517,578 | $1,643,101913 claims |
| Acadia Pharmaceuticals IncNuplazid | $77,173 | $1,400,907227 claims |
| MDD US Operations, LLCGocovri | $124,429 | $617,342141 claims |
| Kyowa Kirin, Inc.Nourianz | $267,940 | $531,933178 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $528,560 | $388,77789 claims |
| NovartisTasigna | $216 | $161,58416 claims |
| UCB, Inc.Neupro | $8,979 | $122,29057 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $24,591 | $118,27646 claims |
| Acorda Therapeutics, IncInbrija | $148,211 | $81,84618 claims |
| Lilly USA, LLCOlanzapine | $290 | $1,52819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.
Other neurology in Alexandria
- Simon FishmanAlexandria$1.6M
- John CochranAlexandria$79K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Robert ShinCharlottesville$2.2M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
- Rahul DaveFairfax$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.